Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus.
作者信息
Cogliano Vincent J, Corsini Emanuela, Fournier Agnès, Nelson Heather H, Sergi Consolato M, Antunes Alexandra M M, Cahoon Elizabeth K, Chen Guosheng, Duarte-Salles Talita, Engels Eric, Fu Jingqi, Germolec Dori, Ghiasvand Reza, Hicks Blánaid, Jean-Claude Bertrand J, Jena Gopabandhu, Lerche Catharina M, Li Xilin, Lupattelli Angela, Ong Thomas P, Vega Libia, Withrow Diana R, Boxall Alistair B A, Benbrahim-Tallaa Lamia, de Conti Aline, Kunzmann Andrew, Pasqual Elisa, Wedekind Roland, Deng Xiaobei, Mahamat-Saleh Yahya, Majidi Azam, Peruchet-Noray Laia, Rezende Da Silva Julia, Suonio Eero, Viegas Susana, Zhai Yue, Mattock Heidi, Facchin Caterina, Schubauer-Berigan Mary K, Madia Federica
机构信息
International Agency for Research on Cancer, Lyon, France.
International Agency for Research on Cancer, Lyon, France; International Agency for Research on Cancer, Lyon, France.
出版信息
Lancet Oncol. 2025 Jan;26(1):15-16. doi: 10.1016/S1470-2045(24)00685-5. Epub 2024 Nov 29.
Abstract
摘要
相似文献
1
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus.氢氯噻嗪、伏立康唑和他克莫司的致癌性。
Lancet Oncol. 2025 Jan;26(1):15-16. doi: 10.1016/S1470-2045(24)00685-5. Epub 2024 Nov 29.
2
Evaluation of the tacrolimus drug interaction with voriconazole vs clotrimazole in heart transplant recipients.心脏移植受者中他克莫司与伏立康唑和克霉唑药物相互作用的评估。
JHLT Open. 2023 Dec 24;4:100048. doi: 10.1016/j.jhlto.2023.100048. eCollection 2024 May.
3
Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.伏立康唑对一名肝移植受者及人肝微粒体中他克莫司代谢的抑制作用。
Antimicrob Agents Chemother. 2002 Sep;46(9):3091-3. doi: 10.1128/AAC.46.9.3091-3093.2002.
4
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.细胞色素P450 2C19基因多态性对与伏立康唑合用时他克莫司药代动力学的影响。
J Clin Pharmacol. 2016 Apr;56(4):408-13. doi: 10.1002/jcph.605. Epub 2015 Oct 8.
5
Relationship between the blood concentrations of tacrolimus and voriconazole in hematopoietic stem cell transplant recipients
.造血干细胞移植受者中他克莫司与伏立康唑血药浓度之间的关系
Int J Clin Pharmacol Ther. 2019 Nov;57(11):561-566. doi: 10.5414/CP203539.
6
Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.伏立康唑对肾移植受者他克莫司代谢的影响。
J Clin Pharm Ther. 2010 Feb;35(1):121-4. doi: 10.1111/j.1365-2710.2009.01070.x.
7
Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.基于生理的药代动力学建模指导下，他克莫司与伏立康唑在不同CYP3A5和CYP2C19等位基因患者中的合理联用。
Toxicol Appl Pharmacol. 2023 May 1;466:116475. doi: 10.1016/j.taap.2023.116475. Epub 2023 Mar 16.
8
It cuts both ways: A single-center retrospective review describing a three-way interaction between flucloxacillin, voriconazole and tacrolimus.它具有两面性：一项单中心回顾性研究描述了氟氯西林、伏立康唑和他克莫司之间的三向相互作用。
Int J Antimicrob Agents. 2023 Sep;62(3):106908. doi: 10.1016/j.ijantimicag.2023.106908. Epub 2023 Jun 28.
9
CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.CYP3A5 基因型依赖性他克莫司与伏立康唑在中国肾移植患者中的药物-药物相互作用。
Ann Pharmacother. 2024 Jun;58(6):605-613. doi: 10.1177/10600280231197399. Epub 2023 Sep 13.
10
Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: A semiphysiologically based population pharmacokinetic modeling approach.成人肝移植受者中他克莫司与伏立康唑药物相互作用的个体剂量推荐：一种基于半生理学的群体药代动力学建模方法。
Eur J Pharm Sci. 2023 May 1;184:106405. doi: 10.1016/j.ejps.2023.106405. Epub 2023 Feb 10.
本文引用的文献
1
Voriconazole metabolism is associated with the number of skin cancers per patient.伏立康唑的代谢与每位患者的皮肤癌数量有关。
Arch Dermatol Res. 2024 May 31;316(6):303. doi: 10.1007/s00403-024-03135-5.
2
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.2022 年世卫组织副神经节瘤和嗜铬细胞瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6. Epub 2022 Mar 13.
3
Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.美国使用含氢氯噻嗪产品与非黑色素瘤皮肤癌风险的相关性。
JNCI Cancer Spectr. 2021 Feb 4;5(2). doi: 10.1093/jncics/pkab009. eCollection 2021 Apr.
4
Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States.美国肺移植受者中伏立康唑与角质形成细胞癌风险。
JAMA Dermatol. 2020 Jul 1;156(7):772-779. doi: 10.1001/jamadermatol.2020.1141.
5
Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark.氢氯噻嗪的使用与非黑色素瘤皮肤癌风险：来自丹麦的全国病例对照研究。
J Am Acad Dermatol. 2018 Apr;78(4):673-681.e9. doi: 10.1016/j.jaad.2017.11.042. Epub 2017 Dec 4.
6
Hydrochlorothiazide use is strongly associated with risk of lip cancer.氢氯噻嗪的使用与唇癌风险密切相关。
J Intern Med. 2017 Oct;282(4):322-331. doi: 10.1111/joim.12629. Epub 2017 Jun 6.
7
A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study.多步伏立康唑相关光毒性途径可能导致皮肤癌：来自法国全国性研究的结果。
Clin Infect Dis. 2013 Dec;57(12):e182-8. doi: 10.1093/cid/cit600. Epub 2013 Sep 17.
8
Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression.现代免疫抑制时代美国肾移植后的移植后淋巴细胞增生性疾病
Transplantation. 2005 Nov 15;80(9):1233-43. doi: 10.1097/01.tp.0000179639.98338.39.
9
Toxicology and Carcinogenesis Studies of Hydrochlorothiazide (CAS No. 58-93-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).氢氯噻嗪（CAS编号：58-93-5）在F344/N大鼠和B6C3F1小鼠中的毒理学和致癌性研究（饲料研究）
Natl Toxicol Program Tech Rep Ser. 1989 Jul;357:1-194.
10
Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats.
Toxicol Ind Health. 1987 Sep;3(3):413-22. doi: 10.1177/074823378700300313.
Zotero 插件